Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viatab
- Development stage
- Discontinued
- Lead developer
- Ipsen
- Administration
- Oral, Intramuscular
01
Overview
Viatab is an investigational drug developed by Biodel as one of its five diabetes projects. It was part of a portfolio of diabetes treatments that received a $1.2 million grant from the Internal Revenue Service (IRS) under the therapeutic discovery tax credit program, established by the Patient Protection and Affordable Act of 2010. Further details regarding its specific mechanism of action or formulation are not provided in the available context.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Viatab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viatab.